
Results
19
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
19 companies
Axsome Therapeutics
Market Cap: US$10.6b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$206.53
7D
10.2%
1Y
77.3%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$518.66
7D
-0.3%
1Y
69.3%
Insmed
Market Cap: US$28.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$140.01
7D
3.0%
1Y
92.9%
Ionis Pharmaceuticals
Market Cap: US$12.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$75.45
7D
4.5%
1Y
124.3%
Alnylam Pharmaceuticals
Market Cap: US$39.5b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$297.93
7D
-3.4%
1Y
8.9%
Ascendis Pharma
Market Cap: US$13.6b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
ASND
US$228.71
7D
0.9%
1Y
n/a
Neurocrine Biosciences
Market Cap: US$13.3b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$134.07
7D
4.7%
1Y
22.2%
BeOne Medicines
Market Cap: US$32.7b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$297.14
7D
-0.6%
1Y
16.9%
BridgeBio Pharma
Market Cap: US$13.4b
A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BBIO
US$68.99
7D
-7.4%
1Y
80.5%
AbbVie
Market Cap: US$365.4b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$208.16
7D
5.5%
1Y
6.2%
Jazz Pharmaceuticals
Market Cap: US$12.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$208.06
7D
3.4%
1Y
76.0%
Eli Lilly
Market Cap: US$859.0b
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$967.93
7D
11.5%
1Y
17.8%
Natera
Market Cap: US$29.6b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$211.56
7D
3.5%
1Y
34.4%
Viatris
Market Cap: US$17.5b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.20
7D
2.6%
1Y
76.9%
Royalty Pharma
Market Cap: US$29.3b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$50.20
7D
1.1%
1Y
52.1%
Merck
Market Cap: US$277.0b
Operates as a healthcare company worldwide.
MRK
US$113.11
7D
2.6%
1Y
36.5%
Elanco Animal Health
Market Cap: US$11.2b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.51
7D
1.9%
1Y
133.3%
Waters
Market Cap: US$30.1b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$301.88
7D
0.7%
1Y
-13.3%
BioMarin Pharmaceutical
Market Cap: US$10.4b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$55.46
7D
3.1%
1Y
-10.6%